Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI

Stock Information for Mason Resources Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Mason Resources Inc.

Theratechnologies Announces Completion of Acquisition by Future Pak
Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak
Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak
Theratechnologies Announces Availability of EGRIFTA WR(TM) (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy
Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote "FOR" the Proposed Plan of Arrangement with Future Pak
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
Theratechnologies Reports Financial Results for the Second Quarter 2025
Theratechnologies to Announce Second Quarter 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.